Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: gianotti n. Infection. 2007 Dec;35(6):451-6. doi: 10.1007/s15010-007-7120-x. Epub 2007 Nov 21. Infection. 2007. PMID: 18034204 Clinical Trial.
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).
Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M; ARCA Collaborative Group. Rusconi S, et al. Among authors: gianotti n. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):373-5. doi: 10.1097/QAI.0b013e3181378f73. J Acquir Immune Defic Syndr. 2007. PMID: 18090302 No abstract available.
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Santoro MM, et al. Among authors: gianotti n. Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23. Infection. 2009. PMID: 19169632
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
272 results